Skip to main content

Advertisement

Log in

New glycemic targets for patients with diabetes from the Japan Diabetes Society

  • Report of the committee
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

In the “Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013,” a new concept of glycemic control in patients with diabetes in Japan has been declared from the Japan Diabetes Society. The main objective value of HbA1c was set to <7% from the perspective of preventing microvascular complications. On the other hand, the objective in cases where objectives can be attained by appropriate dietary or exercise therapy or during pharmacotherapy without the occurrence of side effects such as hypoglycemia was set to <6%, and the objective in cases where intensification of treatment was considered difficult because of the side effects such as hypoglycemia or for other reasons was set to <8%. Treatment objectives should be established individually, considering the age, duration of disease, organ damage, risk of hypoglycemia, support structure, etc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.

    Article  CAS  PubMed  Google Scholar 

  2. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.

    Article  CAS  PubMed  Google Scholar 

  3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

    Article  CAS  PubMed  Google Scholar 

  4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.

    Article  PubMed  Google Scholar 

  5. Gerstein HC, Miller ME, Byington BP, Action to control cardiovascular risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  CAS  PubMed  Google Scholar 

  6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ito C, Maeda R, Ishida S, et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50:225–30.

    Article  CAS  PubMed  Google Scholar 

  8. Yamamoto-Honda R, Kitazato H, Hashimoto S, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J. 2008;55:913–23.

    Article  CAS  PubMed  Google Scholar 

  9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.

    Article  Google Scholar 

  11. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  12. Balkau B, Hu G, Qiao Q, DECODE Study Group; European Diabetes Epidemiology Group, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47:2118–28.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This new concept was initially described in “Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013” in Japanese and was widely announced at the 56th annual meeting of the Japan Diabetes Society (JDS) held in Kumamoto, Japan, in 2013 and therefore called “Kumamoto Declaration 2013.” The English-language edition of “Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013,” which was simplified for publication, appeared on the JDS website in May 2014. We would like to thank the committee members of “Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013” and the Directors of JDS for their contribution to establishing this concept.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eiichi Araki.

Ethics declarations

Conflict of interest

Eiichi Araki has received honoraria for lectures from Drug Company Astellas Pharma Inc., and honoraria for manuscripts from Medical Review Co., Ltd., and Total clinical research grants from Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Taisho Pharmaceutical Holdings Co., Ltd., Masakazu Haneda has received honoraria for lectures from Drug Companies Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Total clinical research grants from Astellas Pharma Inc., Ono Pharmaceutical Co., LTD., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited., and MSD, Kohjiro Ueki has received honoraria for lectures from Drug Company MSD, and courses endowed by companies, etc. from Drug Companies MSD, Novo Nordisk Pharma Ltd., and Boehringer Ingelheim GmbH, Masato Kasuga, Takeshi Nishikawa, Tatsuya Kondo, and Takashi Kadowaki have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Araki, E., Haneda, M., Kasuga, M. et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetol Int 7, 327–330 (2016). https://doi.org/10.1007/s13340-016-0297-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-016-0297-4

Keywords

Navigation